Shanghai Henlius Biotech, Inc. has entered into a licensing and supply agreement for commercializing its adalimumab biosimilar with Pakistan based company Getz Pharma, known for formulation development, manufacturing and marketing of pharmaceutical products.
Addressing “the large unmet demand for adalimumab,” Henlius said, “Leveraging Getz Pharma’s strong business network in South Asia, Southeast Asia, Africa and the CIS, the commercial layout of [adalimumab] will be expanded to emerging markets, and Henlius will bring more high-quality treatment options to patients in these
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Generics Bulletin for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?